Lexeo Therapeutics, Inc. Watch

from 10-Q 38 pages List of Appendices

from 10-Q 11 pages Employment Agreement for Jose Manuel Otero, PH.D

from 10-Q 47 pages Lexeo Therapeutics, Inc. 2021 Equity Incentive Plan 1

from S-1 2 pages Jenny Robertson Chief Business and Legal Officer Lexeo Therapeutics, Inc. 345 Park Avenue South, 6th Floor New York, Ny 10010 via Email: Jrrobertson@lexeotx.com Re: Third Amendment

from S-1 12 pages Employment Agreement for Sandi See Tai, M.D

from S-1 13 pages Employment Agreement for Eric Adler, M.D

from 10-K 36 pages Common Stock Purchase Agreement by and Among Lexeo Therapeutics, Inc., and the Purchasers March 11, 2024 1

from S-1/A 11 pages Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan Adopted by the Board of Directors: October 13, 2023 Approved by the Stockholders: October 13, 2023

from S-1/A 51 pages Lexeo Therapeutics, Inc. 2023 Equity Incentive Plan Adopted by the Board of Directors: October 13, 2023 Approved by the Stockholders: October 13, 2023

from S-1 42 pages License Agreement

from S-1 24 pages Research Collaboration Agreement

from S-1 4 pages ; and 5) Paragraph 5.1 Is Hereby Amended to Read as Follows: 5.1 Patent Prosecution and Maintenance

from S-1 3 pages Re: 1st Amendment to the First License Agreement by and Between Lexeo Therapeutics, Inc. (Hereinafter “Licensee”) and Cornell University (“Cornell”) (Each a “Party”) Effective May 28, 2020 (Cornell Contract [***]) (The “First License Agreement”) and 2nd Amendment to the Second License Agreement by and Between the Parties Effective May 28, 2020, Amended a First-Time Effective January 13, 2022 (Cornell Contract [***]) (The “Second License Agreement”) Effective the Date of the Last Signature Hereto (“Amendment Date”), the Parties Agree to Hereby Modify the First License Agreement and the Second License Agreement as Follows: 1) the Parties Acknowledge That Licensee Changed Its Name and Form From Lexeo Therapeutics, LLC, a Delaware Limited Liability Company, to Lexeo Therapeutics, Inc., a Corporation Under the Laws of Delaware, on November 20, 2020. 2) Paragraph 3.1(d)(iii) of the First License Agreement and of the Second License Agreement Is Hereby Changed From

from S-1 2 pages Re: Amendment #1 to the Second License Agreement by and Between Lexeo Therapeutics, Inc. (Hereinafter “Licensee”) and Cornell University (“Cornell”), as Represented by Its Center for Technology Licensing at Cornell University (Hereinafter “Ctl”) Effective May 28, 2020 (Ctl Contract [***]) (The “Agreement”) Effective as of the Date of Last Signature Below (“Amendment Date”), the Parties Hereby Agree as Follows: 1) the Parties Acknowledge That, After Execution of the Agreement, the Form of Licensee Has Changed From an LLC to a Delaware C Corporation. 2) the Parties Hereby Agree to Add the Following to the List of Original Material in Appendix C: Additional Original Material 15. [***] From Cornell’s Clinical Lot Inventory, Docketed at Cornell as [***]. the Original Material Described in This Line 15 Will Be Used to [***]. for Clarity, No Activities for the Original Material Described in This Line 15 Will Involve Human/Clinical Use. 3) in Consideration for This Amendment, Licensee Shall Pay Cornell [***] as a Material Transfer Fee and [***] as a License Fee, Each Within [***] of the Amendment Date. 4) Except as Expressly Set Forth Herein, Nothing in This Amendment Changes the Terms and Conditions of the Agreement. 5) This Amendment May Be Executed by Electronic Signatures or by Facsimile and in Two (2) or More Counterparts, Each of Which Shall Be Deemed an Original and All of Which Together Shall Constitute but One and the Same Instrument

from S-1 49 pages Second License Agreement Between Lexeo Therapeutics, LLC and Cornell University for Docket No. D-6749 Docket No. D-7225 Docket No. D-7605 Docket No. D-9179 Docket No. D-9325 Docket No. D-9332 Docket No. D-9472 Ctl Contract No. [***]

from S-1 49 pages First License Agreement Between Lexeo Therapeutics, LLC and Cornell University for Docket No. D-6083 Docket No. D-9134 Docket No. D-9179 Docket No. D-9187 Docket No. D-9232 Docket No. D-9325 Docket No. D-9471 Docket No. D-9472 Ctl Contract No. [***]

from S-1 14 pages Research Agreement

from S-1 16 pages Research Agreement

from S-1 16 pages License Agreement

from S-1 21 pages License Agreement Between Arvc Therapeutics, Inc. and the Regents of the University of California for [***]